[1] LaBrecque DR,Abbas Z,Anania F,et al.World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48: 467-473.
[2] Anstee QM,Day CP. The genetics of nonalcoholic fatty liver disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis,2015, 35: 270-290.
[3] Fabio SM, Marcello M, Salvatore P. Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World J Gastroenterol, 2015,21: 11088-11111.
[4] Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive l iver disease. World J Gastrenterrol,2013,19:6969-6978.
[5] He S,McPhau C,Li JZ, et al. A sequence variation(I 148M)in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem,2010,285:6706-6715.
[6] Huang Y,Cohen JC,Hobbs HH.Expression and characterization of a PNPLA3 protein isoform(I148M) associated with nonalcoholic fatty liver disease.J Biol Chem,2011,286: 37085-37093.
[7] Gemma A, Teresa A, Sandra A, et al. PNPLA3 expression is related to liver steatosis in morbidly obese women with non-alcoholic fatty liver disease. Int J Mol Sci,2016,17: 630.
[8] Alisi A, Cianfarani S, Manco M, et al. A non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med,2012,44:29-40.
[9] Miyaaki H, Nakao K.Significance of genetic polymorphisms in patients with nonalcoholic fatty liverdisease. Clin J Gastroenterol,2017,10:201-207.
[10] Romeo S,Kozlitina J,Xing C,et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet, 2008,40:1461-1465.
[11] Salameh H, Hanayneh MA, Masaden M, et al. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum. J Clin Transl Hepaol,2016,4:175-191.
[12] Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.World J Gastroenterol,2016,22: 6742-6756.
[13] Jiang ZG,Tapper EB,Kim M,et al. Genetic determinants of circulating lipoproteins in nonalcoholic fatty liver disease. J Clin Gastroenterol,2017, [Epub ahead of print].
[14] Li Q,Qu HQ,Rentfro AR,et al. PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population.Clin Invest Med,2012,35: E237-E245.
[15] Palmer CN,Maglio C,Pirazzi C,et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.PLoS One,2012,7: e39362.
[16] Surakka I, Horikoshi M, Mgi R, et al. The impact of low-frequency and rare variants on lipid levels. Nat Genet, 2015,47: 589-597.
[17] Mahdessian H,Taxiarchis A,Popov S,et al.TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.Proc Natl Acad Sci USA,2014,111: 8913-8918.
[18] Mahdessian H, Taxiarchis A, Popov S, et al.TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA,2014,111: 8913-8918.
[19] Holmen OL,Zhang H,Fan Y,et al.Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet,2014,46: 345-351.
[20] Musso G, Cipolla U,Cassader M,et al.TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. J Lipid Res.2017,58: 1221-1229.
[21] Krawczyk M,Rau M,Schattenberg JM,et al.Combined effects of the PNPLA3 rs738409,TM6SF2 rs58542926,and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res,2017,58: 247-255.
[22] Pirazzi C, Adiels M,Burza MA,et al.Patatinlike phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.J Hepatol,2012,57: 1276-1282.
[23] Sookoian S, Castao GO, Scian R,et al.Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.Hepatology, 2015,61: 515-525.
[24] Liu YL,Reeves HL,Burt AD, et al.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun,2014,5:4309. |
